Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Rolf Beume"'
Autor:
Armengot M, Rolf Beume, Julio Cortijo, Enrique Artigues, Hermann Tenor, Javier Milara, P Bañuls
Publikováno v:
British Journal of Pharmacology. 166:2243-2262
BACKGROUND AND PURPOSE Mucociliary malfunction occurs in chronic obstructive pulmonary disease (COPD) and compromised functions of ciliated bronchial epithelial cells may contribute to this. Cigarette smoke, a major risk factor for COPD, impairs cili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a244df1ded0ce1eebe57e8776c033a28
https://doi.org/10.1111/j.1476-5381.2012.01929.x
https://doi.org/10.1111/j.1476-5381.2012.01929.x
Autor:
D. Knaack, C. Weiss-Haljiti, A. Dieckmann, Rolf Beume, N. Kaessner, S. Vollert, H. P. Kley, A. Heuser, Guido Hanauer
Publikováno v:
Diabetologia. 55:2779-2788
The cAMP-degrading phosphodiesterase 4 (PDE4) enzyme has recently been implicated in the regulation of glucagon-like peptide-1 (GLP-1), an incretin hormone with glucose-lowering properties. We investigated whether the PDE4 inhibitor roflumilast eleva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9570d49d25b7f9407cf6336df5cc653
https://doi.org/10.1007/s00125-012-2632-z
https://doi.org/10.1007/s00125-012-2632-z
Autor:
Hermann Tenor, Juergen Klar, Armin Hatzelmann, S. Boero, Giovanni A. Rossi, Federica Sabatini, Michela Silvestri, Rolf Beume, Loredana Petecchia
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 23:283-291
The PDE4 inhibitor roflumilast mitigates bleomycin-induced lung fibrotic remodeling in rodents. In the current study it was explored whether roflumilast N-oxide, the active metabolite of roflumilast influences functions of cultured lung fibroblasts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a714688fdda26d7d05077522b976f0f2
https://doi.org/10.1016/j.pupt.2010.02.004
https://doi.org/10.1016/j.pupt.2010.02.004
Autor:
Rolf Beume, Meike Müller, Regina Korolewitz, Armin Braun, Norbert Krug, Lutz Wollin, Heinz-Gerd Hoymann
Publikováno v:
Pharmacology. 83:188-195
Background: Inhibitory effects of roflumilast on responses characteristic of allergic asthma were investigated in a fungal asthma model in BALB/c mice. Methods: Mice were sensitized with Aspergillus antigen (Afu) and exposed to Afu or vehicle, and gi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca9a1e9919d9ce431521777419b3e15
https://doi.org/10.1159/000196814
https://doi.org/10.1159/000196814
Publikováno v:
Journal of Asthma. 42:873-878
This study investigated the effects of roflumilast, a PDE4 inhibitor, on slow-reacting substance of anaphylaxis (SRS-A)-mediated bronchoconstriction and pulmonary leukotriene (LT) release in ovalbumin (OVA)-sensitized and -challenged guinea pigs. Ani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::642bdf71e64357e6b2c013a03491c917
https://doi.org/10.1080/02770900500370858
https://doi.org/10.1080/02770900500370858
Autor:
Ming Yang, Dianne C. Webb, Lutz Wollin, Paul S. Foster, Paul S. Thomas, Rolf Beume, Cristan Herbert, Rakesh K. Kumar
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 307:349-355
Phosphodiesterase (PDE) inhibitors have potential as alternatives or adjuncts to glucocorticoid therapy in asthma. We compared roflumilast (a selective PDE4 inhibitor) with pentoxifylline (a nonselective inhibitor) and dexamethasone in ameliorating t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4381e2b2bcdb5d500f49df9c08e539f9
https://doi.org/10.1124/jpet.103.053819
https://doi.org/10.1124/jpet.103.053819
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 35:91-99
Asthma is considered to be a chronic inflammatory response of the airways characterized by a leukocyte infiltration into the lungs. Whereas lymphocytes and macrophages are involved in the initiation and propagation of inflammation, both neutrophils a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e60593aa73b917c313c711ad54cbb68a
https://doi.org/10.1016/1056-8719(96)00005-6
https://doi.org/10.1016/1056-8719(96)00005-6
Publikováno v:
British journal of pharmacology. 166(8)
Mucociliary malfunction occurs in chronic obstructive pulmonary disease (COPD) and compromised functions of ciliated bronchial epithelial cells may contribute to this. Cigarette smoke, a major risk factor for COPD, impairs ciliary beat frequency (CBF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::03f379a25bda18b35cc711b5a9cc7147
https://pubmed.ncbi.nlm.nih.gov/22385203
https://pubmed.ncbi.nlm.nih.gov/22385203
Publikováno v:
Handbook of experimental pharmacology. (204)
The first pharmacological investigations of phosphodiesterase (PDE) inhibitors were developed with the clinical efficacies of drugs isolated from coffee, cacao and tea but only later their relevant ingredients were identified as xanthines that act as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7fd511046b27395d753b02722138804b
https://pubmed.ncbi.nlm.nih.gov/21695634
https://pubmed.ncbi.nlm.nih.gov/21695634
Publikováno v:
Handbook of experimental pharmacology. (204)
Since more than two decades anti-inflammatory effects of inhibitors of phosphodiesterase-4 have been described in numerous cellular and animal studies and were finally confirmed in clinical trials. The path from an early, pioneering study with Ro20-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::996998a6cb4326eb43edbe7686b79251
https://pubmed.ncbi.nlm.nih.gov/21695636
https://pubmed.ncbi.nlm.nih.gov/21695636